Dnistrian A M, Schwartz M K, Greenberg E J, Smith C A, Dorsa R, Schwartz D C
Memorial Sloan-Kettering Cancer Center, New York.
Int J Biol Markers. 1991 Jul-Sep;6(3):139-43. doi: 10.1177/172460089100600301.
CA 549 is one of several carcinoma associated mucin antigens proposed as a breast cancer tumor marker. In this study, the performance characteristics of the CA 549 assay were validated and the clinical utility of the test was compared with that of other breast cancer markers including CA 15-3, CA M26, CA M29 and carcinoembryonic antigen. The upper limit of normal was established as 15.5 U/ml based on data for 250 control subjects apparently free of disease. Overall, CA 549 had a low negative predictive value (0.51) due to a low sensitivity in the detection of early breast cancer. However, the test had a high positive predictive value (0.93) reflecting a high specificity for the disease. In 56 patients with advanced breast cancer, the sensitivity was 0.71 for CA 549 alone and 0.79-0.84 for CA 549 combined with any of the other markers studied.
CA 549是被提议作为乳腺癌肿瘤标志物的几种癌相关粘蛋白抗原之一。在本研究中，对CA 549检测的性能特征进行了验证，并将该检测的临床效用与其他乳腺癌标志物（包括CA 15-3、CA M26、CA M29和癌胚抗原）的临床效用进行了比较。根据250名明显无疾病的对照受试者的数据，将正常上限设定为15.5 U/ml。总体而言，由于CA 549在早期乳腺癌检测中的低敏感性，其阴性预测值较低（0.51）。然而，该检测具有较高的阳性预测值（0.93），反映出对该疾病具有较高的特异性。在56例晚期乳腺癌患者中，CA 549单独检测的敏感性为0.71，CA 549与所研究的任何其他标志物联合检测的敏感性为0.79 - 0.84。
